

PANACOS PHARMACEUTICALS, INC.

Form S-8 POS

March 12, 2009

As filed with the Securities and Exchange Commission on March 12, 2009

Registration No. 333-94427

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO
FORM S-8
REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Panacos Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of

incorporation or organization)

11-3238476
(IRS Employer

Identification Number)

134 Coolidge Avenue

Watertown, Massachusetts
(Address of Principal Executive Offices)

02472
(Zip Code)

V.I. TECHNOLOGIES, INC. 1999 SUPPLEMENTAL STOCK OPTION PLAN

(Full title of the plan)

Alan W. Dunton, M.D.

President and Chief Executive Officer

Panacos Pharmaceuticals, Inc.

134 Coolidge Avenue

Watertown, Massachusetts 02472

(617) 926-1551

(Name, address, including zip code, and telephone

number, including area code, of agent for service)

Copies to:

Megan N. Gates, Esq.

Mintz, Levin, Ferris, Glovsky & Popeo, P.C.

One Financial Center

Boston, MA 02111

(617) 542-6000

DEREGISTRATION OF UNSOLD SECURITIES

On January 11, 2000, Panacos Pharmaceuticals, Inc., formerly known as V.I. Technologies, Inc. (the Company), filed a registration statement on Form S-8 (File No. 333-94427) (the Registration Statement). The Registration Statement registered a total of 1,000,000 shares of the Company's common stock, par value \$0.01 per share (the Common Stock), to be issued pursuant to the Company's 1999 Supplemental Stock Option Plan. This offering has been terminated because the Company intends to deregister its Common Stock under the Securities Exchange Act of 1934, as amended. Consequently, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offering, the Company hereby removes from registration the securities of the Company that are registered but unsold under the Registration Statement.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts on March 12, 2009.

PANACOS PHARMACEUTICALS, INC.

/s/ Alan W. Dunton, M.D.
Alan W. Dunton, M.D.
President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Alan W. Dunton, M.D. Alan W. Dunton, M.D.	President and Chief Executive Officer and Director	March 12, 2009
/s/ Robert B. Pelletier, CPA, MBA Robert B. Pelletier, CPA, MBA	Vice President of Finance and Principal Accounting Officer	March 12, 2009
/s/ Laurent Fischer, M.D. Laurent Fischer, M.D.	Director	March 12, 2009
/s/ Jeremy Hayward-Surry Jeremy Hayward-Surry	Director	March 12, 2009